Notice to Readers: Availability of Additional Trivalent Inactivated Influenza Vaccine for Adults (Afluria®)
On September 28, 2007, CSL Biotherapies, Inc., (King of Prussia, Pennsylvania) received approval from the Food and Drug Administration for use of Afluria®, a trivalent inactivated influenza vaccine (TIV) administered intramuscularly in persons aged >18 years (1). Afluria can be used for any adult influenza vaccine indication (2).
The addition of Afluria brings to six (five TIVs and one live, attenuated influenza vaccine) the number of seasonal influenza vaccines licensed for the U.S. market. CDC estimates that manufacturers of the six vaccines will supply a record 132 million doses of influenza vaccine for the 2007--08 influenza season.
Afluria is available in a 0.5 mL preservative-free, single-dose, prefilled syringe and in a 5 mL multidose vial containing 10 doses. Thimerosal, a mercury derivative, is added as a preservative to the multidose vial; each 0.5 mL dose contains 24.5 µg of mercury. Additional information is available from the manufacturer's package insert (3) and CSL Biotherapies, Inc., telephone 888-435-8633.
- Food and Drug Administration. Additional influenza vaccine approved for upcoming influenza season: approval increases available doses to record level. Rockville, MD: Food and Drug Administration; 2007. Available at http://www.fda.gov/bbs/topics/news/2007/new01714.html.
- CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. MMWR 2007;56(No. RR-6).
- Afluria [package insert]. King of Prussia, PA: CSL Biotherapies, Inc.; 2007. Available at http://www.afluria.com/pi.pdf.
All MMWR HTML versions of articles are electronic conversions from typeset documents.
This conversion might result in character translation or format errors in the HTML version.
Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr)
and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S.
Government Printing Office (GPO), Washington, DC 20402-9371;
telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to email@example.com.